Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Forte Biosciences, Inc.    FBRX

FORTE BIOSCIENCES, INC.

(FBRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Forte Biosciences Shares Higher After Truist Initiates Coverage

share with twitter share with LinkedIn share with facebook
08/25/2020 | 12:22pm EDT

By Stephen Nakrosis

Shares of Forte Biosciences Inc. are trading higher on the Nasdaq Tuesday after Truist initiated coverage of the company's stock with a "buy" recommendation and set a price target of $70 per share.

At 11:32 a.m. EDT, Forte shares had gained 13.28% to trade at $27.98. Volume topped 113,000 shares, above the stock's 65-day average volume of 52,209 shares.

In a report Tuesday, Truist said Forte is developing a treatment for inflammatory skin diseases, FB-401, which will be "initially focused on pediatric atropic dermatitis patients, who have a high unmet need for safe/efficacious treatments."

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 


Stocks mentioned in the article
ChangeLast1st jan.
FACEBOOK INC 2.36% 267.56 Delayed Quote.30.36%
FORTE BIOSCIENCES, INC. -2.25% 34.76 Delayed Quote.334.61%
NASDAQ COMP. 0.33% 11516.494418 Delayed Quote.27.93%
TRUIST FINANCIAL CORPORATION 1.25% 42.09 Delayed Quote.-25.27%
share with twitter share with LinkedIn share with facebook
All news about FORTE BIOSCIENCES, INC.
10/16FORTE BIOSCIENCES, INC. : Reports Inducement Grants Under NASDAQ Listing Rules
BU
09/29FORTE BIOSCIENCES, INC. : Announces First Patient Dosed in the Clinical Trial of..
BU
09/09FORTE BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exh..
AQ
09/09FORTE BIOSCIENCES, INC. : Announces Full Publication of Phase 1/2 Data in Scienc..
BU
09/04FORTE BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Terminatio..
AQ
08/25Forte Biosciences Shares Higher After Truist Initiates Coverage
DJ
08/25FORTE BIOSCIENCES, INC. : Reports Inducement Grants Under Nasdaq Listing Rules
BU
08/10FORTE BIOSCIENCES, INC. : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
08/10FORTE BIOSCIENCES, INC. : Financial Statements and Exhibits (form 8-K)
AQ
08/10FORTE BIOSCIENCES : Financial Statements and Exhibits (form 8-K/A)
AQ
More news
Financials (USD)
Sales 2020 - - -
Net income 2020 -48,9 M - -
Net Debt 2020 16,0 M - -
P/E ratio 2020 -4,94x
Yield 2020 -
Capitalization 398 M 398 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 5
Free-Float 74,0%
Chart FORTE BIOSCIENCES, INC.
Duration : Period :
Forte Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FORTE BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 85,00 $
Last Close Price 35,56 $
Spread / Highest target 209%
Spread / Average Target 139%
Spread / Lowest Target 96,9%
EPS Revisions
Managers
NameTitle
Paul A. Wagner President, Chief Executive Officer & Director
Anthony A. Riley Chief Financial Officer
Daniel J. Burge Head-Clinical Development
Thomas E. Darcy Director
Lawrence F. Eichenfield Director
Sector and Competitors
1st jan.Capitalization (M$)
FORTE BIOSCIENCES, INC.344.61%398
GILEAD SCIENCES, INC.-6.79%75 938
REGENERON PHARMACEUTICALS55.31%61 364
VERTEX PHARMACEUTICALS0.71%57 436
WUXI APPTEC CO., LTD.60.41%38 230
BEIGENE, LTD.81.90%27 326